Abstract: The invention relates to the use of core/shell particles, the core of which essentially comprises a degradable polymer with an essentially mono-disperse size distribution and the shell of which forms a matrix, which can be pyrolysed to give a carbon matrix, for the production of shaped bodies with regularly-arranged cavities and the corresponding shaped bodies.
Type:
Application
Filed:
November 10, 2004
Publication date:
July 12, 2007
Applicant:
MERCK PATENT GMBH
Inventors:
Holger Winkler, Goetz Hellmann, Tilmann Ruhl, Peter Spahn
Abstract: Novel compounds of the formula (I), in which X—Y-D-E, R1, R2 and R3 have the meanings indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours
Type:
Application
Filed:
January 7, 2005
Publication date:
July 12, 2007
Applicant:
MERCK PATENT GMBH
Inventors:
Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
Abstract: The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
Abstract: Hybrid sol comprising [SiOx(OH)y]n particles, where 0<y<4 and 0<x<2, which consist of a mixture of a first fraction of particles having a particle size of 4–15 nm and a second fraction of particles having a mean particle size of 15–60 nm, water and a solvent; obtainable by hydrolytic polycondensation of tetraalkoxysilanes in an aqueous, solvent-containing medium with addition of a monodisperse silicon oxide hydroxide sol having a mean particle size of 15–60 nm and a maximum standard deviation of 20%, and the preparation and use thereof.
Type:
Grant
Filed:
September 19, 2002
Date of Patent:
July 10, 2007
Assignee:
Merck Patent, GmbH
Inventors:
Walther Glaubitt, Monika Kursawe, Andreas Gombert, Thomas Hofmann
Abstract: The invention relates to the identification and characterization of a grass-pollen allergen, and to the recombinant DNA molecule encoding therefore, and to corresponding DNA and peptide sequences.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
July 10, 2007
Assignee:
Merck Patent GmbH
Inventors:
Helmut Fiebig, Roland Suck, Oliver Cromwell
Abstract: An iridescent multilayer pigment having at least two or more layers of metal oxides containing one or more metals selected from Ce, Sn, Ti, Fe, Zn and Zr which are coated onto the surface of thin platelet-like substrates. The inventive pigments show high brilliance and high chroma, in particular in cases in which thin platelet-like substrates having a fine average particle diameter are used. The pigment is useful in paints, printing inks, lacquers, plastics, dopants for laser marking, non-dusting pigment products, non-dusting pigment granules or cosmetics.
Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
Type:
Application
Filed:
December 29, 2006
Publication date:
July 5, 2007
Applicant:
Merck Patent GmbH
Inventors:
Michael Super, Jonathan Davis, Pascal Stein
Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
Type:
Application
Filed:
December 29, 2006
Publication date:
July 5, 2007
Applicant:
Merck Patent GmbH
Inventors:
Gordon Webster, Suzanne McKenzie, Kin-Ming Lo, Pascal Stein
Abstract: The invention relates to the use of gelation moulds made from hydrophobicized glass tubes for the production of monolithic mouldings as sorbents for chromatography.
Abstract: The invention relates to a process for the production of chromatography columns or capillaries containing sorbents of monolithic mouldings which can remain directly in their gelation mould after production. This is achieved by the process according to the invention, in which the gelation mould is repeatedly filled with the monomer sol.
Abstract: The invention relates to a method for the production of high-purity, heteroleptic, ortho-metallated, organometallic compounds of application as a functional material for colouring components in a wide range of applications within the widest sense of the electronics industry. A method is thus used for the cleavage of a bridged metal dimer with organometallic substances. Dihalo complexes, which may be used as monomers for polymerisations, in particular, may be produced thus.
Type:
Application
Filed:
October 21, 2004
Publication date:
June 14, 2007
Applicant:
Merck Patent GmbH
Inventors:
Philipp Stössel, Arne Busing, Ingrid Bach
Abstract: The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding domain of same or different ErbB receptors, these antibodies are more effective with respect to inhibition and down-regulation of the ErbB receptor and the corresponding signaling cascade.
Abstract: The present invention relates to effect pigments based on thin glass flakes and to a method for the production of such pigments. The resulting pigment can be used in any application for which pearlescent pigments have been heretofore used such as, for example, in plastics, paints, inks, cosmetic formulations, coatings including solvent or waterborne automotive paint systems, powder coatings, inks and agriculture foils.
Type:
Grant
Filed:
April 11, 2002
Date of Patent:
June 5, 2007
Assignee:
Merck Patent GmbH
Inventors:
Ralf Anselmann, Klaus Ambrosius, Marcus Mathias
Abstract: The present invention relates to conjugated polymers which comprise coumarin structural units or related units of the formula (1). The materials according to the invention exhibit significantly higher photostability than materials in accordance with the prior art and are therefore more suitable for use in polymeric organic light-emitting diodes.
Type:
Application
Filed:
November 24, 2004
Publication date:
May 31, 2007
Applicant:
Merck Patent GmbH
Inventors:
Amir Parham, Susanne Heun, Aurelie Falcou, Heinrich Becker
Abstract: The present invention describes electroluminescent elements comprising cathode and anode and at least one emission layer, where this comprises at least one matrix material A comprising certain elements and at least one emitter layer B which emits light from the triplet state.
Type:
Application
Filed:
February 10, 2005
Publication date:
May 31, 2007
Applicant:
Merck Patent GmbH
Inventors:
Esther Breuning, Anja Gerhard, Horst Vestweber, Philipp Stoessel
Abstract: The present invention describes novel 2,1,3-benzothiadiazole-containing compounds. Such compounds can be used as active components (=functional materials) in a variety of different applications which can in the widest sense be considered part of the electronics industry.
Type:
Grant
Filed:
June 14, 2003
Date of Patent:
May 29, 2007
Assignee:
Merck Patent GmbH
Inventors:
Philipp Stössel, Amir Parham, Horst Vestweber, Hubert Spreitzer
Abstract: The invention relates to the improvement of phosphorescing organic electroluminescent devices characterized in that the emission layer, which consists of a matrix material which is doped with at least one phosphorescing emitter, directly adjoins an electrically conducting layer.
Type:
Application
Filed:
November 24, 2004
Publication date:
May 24, 2007
Applicant:
Merck Patent GmbH
Inventors:
Anja Gerhard, Horst Vestweber, Philipp Stossel
Abstract: The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells such as tumor cells overexpressing survivin.
Type:
Application
Filed:
September 26, 2006
Publication date:
May 10, 2007
Applicant:
Merck Patent GmbH
Inventors:
Stephen Gillies, Thore Hettmann, Pascal Stein, Stephan Klinz
Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.
Type:
Application
Filed:
October 14, 2004
Publication date:
May 3, 2007
Applicant:
Merck Patent GmbH
Inventors:
Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
Abstract: The invention relates to a photostable liquid-crystalline medium comprising at least one compound of the formula I and at least one compound of the formula II and to the use thereof for electro-optical purposes, and to displays containing this medium.
Type:
Grant
Filed:
September 25, 2003
Date of Patent:
May 1, 2007
Assignee:
Merck Patent GmbH
Inventors:
Atsutaka Manabe, Ulrich Heywang, Detlef Pauluth, Michael Heckmeier, Peer Kirsch, Elvira Montenegro